baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Bonus Zert GILD 31.12.2024/ DE000VM96JZ2 /

2024-06-19 9:22:16 AM	Chg.-1.41	Bid8:00:03 PM	Ask8:00:03 PM	Underlying	Strike price	Expiration date	Option type
76.06EUR	-1.82%	- Bid Size: -	- Ask Size: -	Gilead Sciences Inc	- USD	2024-12-31	Call

GlobeNewswire 06-18 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 06-17 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 06-10 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 05-22 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 05-14 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GlobeNewswire 05-09 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...

GlobeNewswire 05-09 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 05-08 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire 05-08 Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 04-29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 04-19 ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...

GlobeNewswire 04-10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...

GlobeNewswire 04-03 Opthea Appoints Sujal Shah to the Board of Directors

GlobeNewswire 04-02 Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

GlobeNewswire 04-02 Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

GlobeNewswire 04-01 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...

GlobeNewswire 03-28 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...

GlobeNewswire 03-28 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

GlobeNewswire 03-28 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire 03-22 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...

GlobeNewswire 03-18 CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards

GlobeNewswire 03-11 Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...

GlobeNewswire 02-29 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...

GlobeNewswire 02-29 Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...

GlobeNewswire 02-28 CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...

BVT Bonus Zert GILD 31.12.2024/ DE000VM96JZ2 /

If you wish to receive reply to your feedback, please provide your email address.